Raymond James Maintains Hold Rating for Amgen Following Analyst's Past Performance

Raymond James analyst Christopher Raymond has maintained Amgen (AMGN.US) with a hold rating. This decision is based on his past performance, which shows a success rate of 43.4% and a total average return of 0.8% over the past year, according to TipRanks data.

Note that these figures are calculated based on the analyst's successful ratings, divided by his total number of ratings over the past year. A successful rating is one where the TipRanks' virtual portfolio has earned a positive return from the stock.